Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02471716 · ClinicalTrials.gov registry record · Phase 1

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

A Phase 1 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, sponsored by Five Prime Therapeutics.

Completed
Registry status
Phase 1
Development phase
66
Enrollment target
12
Study locations

NCT02471716 is a Phase 1 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis that has completed, run by Five Prime Therapeutics. The registered enrollment target is 66 participants, below the 110-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (40% lower). The trial reports 12 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02471716, a Phase 1 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, has completed, sponsored by Five Prime Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
66 participants
Enrollment target
12
Study locations

Study Summary

This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.

Conditions Studied

Tenosynovial Giant Cell Tumor Pigmented Villonodular Synovitis

Interventions

  • BIOLOGICAL FPA008

Study Locations (12)

Other

  • Institut Bergonie- CRLCC de Bordeaux et du Sud-Ouest - Bordeaux
  • Centre Léon Bérard - Lyon
  • Leiden University Medical Center - Leiden
  • Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie - Warsaw
  • University Hospitals Birmingham NHS Foundation Trust - Birmingham
  • Oxford University Hospital NHS Trust - Oxford

California

  • Cedars-Sinai Medical Center - Los Angeles
  • Sarcoma Oncology Research Center LLC - Santa Monica
  • Stanford Medicine - Stanford

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Texas

  • The University of Texas, MD Anderson Cancer Center - Houston

Jongno-gu

  • Seoul National University Hospital - Seoul

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2015-06
Est. Completion 2020-04-30
Phase Phase 1

Sponsor

Five Prime Therapeutics

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02471716

The ClinicalTrials.gov registry entry for NCT02471716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 110-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (40% lower). The listed sponsor is Five Prime Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Tenosynovial Giant Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which FPA008 is the first listed.

NCT02471716 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02471716 about?

NCT02471716 is a clinical study titled "Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor". This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.

What is the current status of trial NCT02471716?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-06. Estimated completion is 2020-04-30.

What conditions does trial NCT02471716 study?

This clinical trial studies the following conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis.

What interventions are being tested in trial NCT02471716?

The interventions under investigation include: FPA008 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02471716?

This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02471716 being conducted?

This trial has 12 study locations across California, Massachusetts, Texas, Jongno-gu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tenosynovial Giant Cell Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Tenosynovial Giant Cell Tumor

All registered trials for this condition

Pigmented Villonodular Synovitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.